Autor(es):
Sousa-Pinto, B ; Louis, R ; Anto, J M ; Amaral, R ; Sá-Sousa, A ; Czarlewski, W ; Brussino, L ; Canonica, G W ; Chaves Loureiro, C ; Cruz, A A ; Gemicioglu, B ; Haahtela, T ; Kupczyk, M ; Kvedariene, V ; Larenas-Linnemann, D E ; Okamoto, Y ; Ollert, M ; Pfaar, O ; Pham-Thi, N ; Puggioni, F ; Regateiro, F. S. ; Romantowski, J ; Sastre, J ; Scichilone, N ; Taborda-Barata, L ; Ventura, M T ; Agache, I ; Bedbrook, A ; Becker, S ; Bergmann, K C ; Bosnic-Anticevich, S ; Bonini, M ; Boulet, L-P ; Brusselle, G ; Buhl, R ; Cecchi, L ; Charpin, D ; de Blay, F ; Del Giacco, S ; Ivancevich, J C ; Jutel, M ; Klimek, L ; Kraxner, H ; Kuna, P ; Laune, D ; Makela, M ; Morais-Almeida, M ; Nadif, R ; Niedoszytko, M ; Papadopoulos, N G ; Papi, A ; Patella, V ; Pétré, B ; Rivero Yeverino, D ; Cordeiro, Carlos Robalo ; Roche, N ; Rouadi, P W ; Samolinski, B ; Savouré, M ; Shamji, M H ; Sheikh, A ; Suppli Ulrik, C ; Usmani, O S ; Valiulis, A ; Yorgancioglu, A ; Fonseca, J A ; Costa, E M ; Bousquet, J
Data: 2023
Identificador Persistente: https://hdl.handle.net/10316/114492
Origem: Estudo Geral - Universidade de Coimbra
Assunto(s): Asthma; Adherence; Inhaledcorticosteroids; Formoterol; Long-acting-b2agonist
Descrição
Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
